Table 5.

Pharmacokinetic variables for irinotecan and SN-38 in patients also receiving EIAEDs at a dose of 500 mg/m2

Pharmacokinetic variablesNABTC 9801 (32) irinotecan alone (n = 3)*NABTC 9907 (current study) temozolomide and irinotecan (n = 6)
Irinotecan CL (L/h/m2)22.123.1
SN-38 AUC (ng × h/mL), dose normalized0.460.31
SN-38/irinotecan (% ratio)1.20.8
  • Abbreviation: CL, systemic clearance.

  • * Values reported are mean (±SD).